CDT Equity (CDT) vs Decoy Therapeutics (DCOY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Decoy Therapeutics is the larger company by market cap ($995,881 vs $32,432), about 30.7 times the size. On valuation, CDT Equity trades at a lower trailing P/E (0.0x vs 0.1x for Decoy Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDT | DCOY |
|---|---|---|
| Share price | $0.80 | $1.52 |
| Market cap | $32.43K | $995.88K |
| 1-day change | -4.31% | -5.59% |
| P/E ratio (TTM) | 0.00 | 0.12 |
| EPS (TTM) | $90,812.50 | $12.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28,400.00 | $55.92 |
| 52-week low | $0.796 | $1.48 |
| Distance from 52-week high | -100.00% | -97.28% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +97.37% |
| Average volume | 188.27K | 2.17M |
| Shares outstanding | 40.54K | 655.18K |
| Employees | 4 | 11 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Decoy Therapeutics is about 30.7 times larger than CDT Equity by market value ($995.88K vs $32.43K).
- Decoy Therapeutics trades at a higher earnings multiple (0.1x vs 0.0x trailing P/E).
About CDT Equity
CDT stock →CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Decoy Therapeutics
DCOY stock →Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
CDT vs DCOY FAQ
Which is bigger, CDT Equity or Decoy Therapeutics?
Decoy Therapeutics (DCOY) is larger, with a market capitalization of $995.88K compared with $32.43K for CDT Equity (CDT).
Which has the lower P/E ratio, CDT or DCOY?
CDT has the lower trailing P/E at 0.0, versus 0.1 for DCOY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are CDT Equity and Decoy Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.